Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$0.55 USD
-0.03 (-5.21%)
Updated Aug 8, 2024 03:58 PM ET
After-Market: $0.55 0.00 (0.00%) 6:08 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for Monopar Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -8.40 | -10.52 | -9.10 | -6.30 | -4.22 |
Depreciation/Amortization & Depletion | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | -1.35 | 1.65 | 0.32 | 0.44 | 0.19 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.90 | 1.64 | 1.47 | 1.20 | 1.01 |
Net Cash From Operating Activities | -7.86 | -7.23 | -7.32 | -4.66 | -3.02 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 4.93 | -4.92 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 4.93 | -4.92 | 0.00 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.07 | 0.11 | 10.94 | 8.18 | 10.33 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.05 | -0.08 | -0.06 | -0.12 | -0.97 |
Net Cash from Financing Activities | 2.03 | 0.03 | 10.88 | 8.18 | 9.35 |
Effect of Exchange Rate Changes | -0.02 | 0.00 | 0.00 | 0.00 | -0.01 |
Net Change In Cash & Equivalents | -0.92 | -12.12 | 3.57 | 3.52 | 6.32 |
Cash at Beginning of Period | 8.19 | 20.30 | 16.74 | 13.21 | 6.89 |
Cash at End of Period | 7.27 | 8.19 | 20.30 | 16.74 | 13.21 |
Diluted Net EPS | -0.61 | -0.83 | -0.73 | -0.58 | -0.45 |
Fiscal Year End for Monopar Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -1.64 | -8.40 | -6.59 | -4.63 |
Depreciation/Amortization & Depletion | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | NA | -0.34 | -1.35 | -1.15 | -0.69 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 0.33 | 1.90 | 1.42 | 0.95 |
Net Cash From Operating Activities | NA | -1.66 | -7.86 | -6.31 | -4.37 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -0.98 | 4.93 | 1.96 | 1.97 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -0.98 | 4.93 | 1.96 | 1.97 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 3.19 | 2.07 | 1.73 | 1.48 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.01 | -0.05 | -0.04 | -0.03 |
Net Cash from Financing Activities | NA | 3.18 | 2.03 | 1.69 | 1.45 |
Effect of Exchange Rate Changes | NA | 0.00 | -0.02 | -0.01 | -0.02 |
Net Change In Cash & Equivalents | NA | 0.54 | -0.92 | -2.67 | -0.97 |
Cash at Beginning of Period | NA | 7.27 | 8.19 | 8.19 | 8.19 |
Cash at End of Period | NA | 7.81 | 7.27 | 5.52 | 7.21 |
Diluted Net EPS | NA | -0.10 | -0.12 | -0.14 | -0.16 |